Overview

JX09 SAD/MAD in Healthy Participants

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 1, randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose study in healthy adult to test the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of JX09 when administered to healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Ji Xing Pharmaceuticals Australia Pty Ltd
Collaborator:
Novotech (Australia) Pty Limited